Fig. 6

Verification of the in vitro and in vivo activity of the identified compounds. a Tumor growth curve of tumor xenografts in C57BL/6 J mice treated with nilotinib (20 mg/kg/day), sorafenib (20 mg/kg/day), and controls on the indicated days (n = 6 mice per group). The circle, triangle, and box denote the average volume of tumors (± SEM), and P values were calculated by the two-sided log-rank test. b Gating based on cell types labeled with different flow cytometry antibodies. SSC-A means cell granularity, CD45 labeled leukocytes, CD3⁺ and CD8⁺ labeled cytotoxic T cells, CD3⁺ and CD49⁺ labeled NK cells, CD11b⁺ and F4/80⁺ labeled macrophages, CD11b⁺ and Ly6G⁺ labeled neutrophils. c, d Cytokine production of stimulated tumor xenograft murine CD8⁺, CD49⁺, F4/80⁺, and Ly6G⁺ cells pretreated with nilotinib, sorafenib, or DMSO (n = 6). e, f Mean SD relative quantity percentage of CD3⁺ + CD8⁺, CD3⁺ + CD49⁺, CD11b⁺ + F4/80⁺, and CD11b⁺ + Ly6G⁺ cells pretreated with nilotinib, sorafenib, or DMSO (n = 6). P values were calculated by the two-sided log-rank test